Skip to main content

Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation

European Journal of Clinical Pharmacology volume 63, pages 39–42 (2007)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Buchen S, Ngampolo D, Melton RG, Hasan C, Zoubek A, Henze G et al (2005) Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 92:480–487

    PubMed  CAS  Google Scholar 

  2. Camitta BM, Holcenberg JS (1978) Safety of delayed leucovorin “rescue” following high-dose methotrexate in children. Med Pediatr Oncol 5:55–59

    PubMed  CAS  Google Scholar 

  3. Canal P, Gamelin E, Vassal G, Robert J (1998) Benefits of pharmacological knowledge in the design and monitoring of cancer chemotherapy. Pathol Oncol Res 4:171–178

    PubMed  CAS  Article  Google Scholar 

  4. Cano JP, Bruno R, Lena N, Favre R, Iliadis A, Imbert AM (1985) Dosage predictions in high-dose methotrexate infusions. Part 1: evaluation of the classic test-dose protocol. Cancer Drug Deliv 2:271–276

    PubMed  CAS  Google Scholar 

  5. Donehower RC, Hande KR, Drake JC, Chabner BA (1979) Presence of 2,4-diamino-N10-methylpteroic acid after high-dose methotrexate. Clin Pharmacol Ther 26:63–72

    PubMed  CAS  Google Scholar 

  6. Donehower RC (1980) Metabolic conversion of methotrexate in man. Recent Results Cancer Res 74:37–41

    PubMed  CAS  Google Scholar 

  7. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR (1979) Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol 3:161–166

    PubMed  Article  CAS  Google Scholar 

  8. Hempel L, Misselwitz J, Fleck C, Kentouche K, Leder C, Appenroth D et al (2003) Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med Pediatr Oncol 40:348–354

    PubMed  Article  Google Scholar 

  9. Huvos AG, Rosen G, Marcove RC (1977) Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med 101:14–18

    PubMed  CAS  Google Scholar 

  10. Iliadis A, Brown AC, Huggins ML (1992) APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput Methods Programs Biomed 38:227–239

    PubMed  Article  CAS  Google Scholar 

  11. Kerr IG, Jolivet J, Collins JM, Drake JC, Chabner BA (1983) Test dose for predicting high-dose methotrexate infusions. Clin Pharmacol Ther 33:44–51

    PubMed  CAS  Article  Google Scholar 

  12. Krause AS, Weihrauch MR, Bode U, Fleischhack G, Elter T, Heuer T et al (2002) Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphom 43:2139–2143

    Article  CAS  Google Scholar 

  13. Minton NP, Atkinson T, Sherwood RF (1983) Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol 156:1222–1227

    PubMed  CAS  Google Scholar 

  14. Peyriere H, Cociglio M, Margueritte G, Vallat C, Blayac JP, Hillaire-Buys D (2004) Optimal management of methotrexate intoxication in a child with osteosarcoma. Ann Pharmacother 38:422–427

    PubMed  Article  Google Scholar 

  15. Pignon T, Lacarelle B, Duffaud F, Guillet P, Catalin J, Durand A et al (1994) Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma. Cancer Chemother Pharmacol 33:420–424

    PubMed  CAS  Google Scholar 

  16. Sand TE, Jacobsen S (1981) Effect of urine pH and flow on renal clearance of methotrexate. Eur J Clin Pharmacol 19:453–456

    PubMed  Article  CAS  Google Scholar 

  17. United States Department of Health and Human Services, Food and Drug Administration (2001) Guidance for Industry Bioanalytical Method Validation

  18. Vallée S, Monjanel-Mouterde S, Bagarry-Liegey D et al (2001) Adaptation individuelle de posologie du méthotrexate (MTX) chez un insuffisant rénal sévère: danger de la méthode bayésienne. J Pharm Clin 20:225–228

    Google Scholar 

  19. Widemann BC, Hetherington ML, Murphy RF, Balis FM, Adamson PC (1995) Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer 76:521–526

    PubMed  Article  CAS  Google Scholar 

  20. Widemann BC, Balis FM, Murphy RF, Sorensen JM, Montello MJ, O’Brien M et al (1997) Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 15:2125–2134

    PubMed  CAS  Google Scholar 

  21. Widemann BC, Sung E, Anderson L, Salzer WL, Balis FM, Monitjo KS et al (2000) Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid. J Pharmacol Exp Ther 294:894–901

    PubMed  CAS  Google Scholar 

  22. Widemann B, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S et al (2004) High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 100:2222–2232

    PubMed  Article  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Laboratoire de Pharmacocinétique et de Toxicocinétique, CHU Timone, 254 rue St Pierre, 13005, Marseille, France

    M.-A. Estève, B. Devictor-Pierre, G. Galy, B. Lacarelle & S. Monjanel-Mouterde

  2. Service de Pédiatrie Oncologique, CHU Timone, 254 rue St Pierre, 13005, Marseille, France

    N. André, C. Coze & J.-L. Bernard

Authors
  1. M.-A. Estève
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Devictor-Pierre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Galy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. André
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Coze
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Lacarelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J.-L. Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Monjanel-Mouterde
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Monjanel-Mouterde.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Estève, MA., Devictor-Pierre, B., Galy, G. et al. Severe acute toxicity associated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation. Eur J Clin Pharmacol 63, 39–42 (2007). https://doi.org/10.1007/s00228-006-0212-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-006-0212-1

Keywords

  • Osteosarcoma
  • Therapeutic Drug Monitoring
  • Leucovorin Rescue
  • Severe Acute Intoxication
  • Main Toxic Metabolite